Published in Clin Infect Dis on October 22, 2012
(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis (2012) 2.26
(1->3) β-D-glucan as a prognostic marker. Clin Infect Dis (2012) 1.08
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis (2007) 4.23
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis (2012) 2.26
In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother (2002) 2.03
Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother (2007) 1.77
Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother (2003) 1.64
In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother (2004) 1.55
In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother (2002) 1.52
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis (2011) 1.42
Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol (2010) 1.24
Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. Diagn Microbiol Infect Dis (2003) 1.15
Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol (2006) 1.14
Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol (2006) 1.10
Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis. J Clin Microbiol (2012) 1.10
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother (2005) 1.06
Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res (2005) 1.02
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother (2006) 1.01
What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med (2014) 1.01
Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? Antimicrob Agents Chemother (2012) 0.97
Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. Int J Antimicrob Agents (2004) 0.97
Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis (2013) 0.96
A web-based endpoint adjudication system for interim analyses in clinical trials. Clin Trials (2009) 0.93
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother (2011) 0.93
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob Agents Chemother (2008) 0.92
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care (2009) 0.91
Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. Arch Med Res (2006) 0.91
In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol (2002) 0.90
Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care (2010) 0.90
Current options in antifungal pharmacotherapy. Pharmacotherapy (2008) 0.90
Cost of a ventilator-associated pneumonia in a shock trauma intensive care unit. Surg Infect (Larchmt) (2005) 0.87
Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother (2008) 0.85
Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother (2004) 0.85
Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis. Clin Ther (2008) 0.84
Ventilator-associated pneumonia: a review. Hosp Pract (1995) (2012) 0.84
Syscan3, a kit for detection of anti-Candida antibodies for diagnosis of invasive candidiasis. J Clin Microbiol (2005) 0.84
Tigecycline : a critical safety review. Expert Opin Drug Saf (2014) 0.81
Therapy of common superficial fungal infections. Dermatol Ther (2004) 0.80
Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis (2005) 0.80
FlindersTechnology Associates (FTA) filter paper-based DNA extraction with polymerase chain reaction (PCR) for detection of Pneumocystis jirovecii from respiratory specimens of immunocompromised patients. J Clin Lab Anal (2007) 0.80
Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit? Crit Care Med (2004) 0.79
Disk diffusion-based methods for determining Candida parapsilosis susceptibility to anidulafungin. Antimicrob Agents Chemother (2003) 0.79
Multicentric hepatic EBV-associated smooth muscle tumors in an AIDS patient: a case report, investigation of mTOR activation and review of the literature. Int J Clin Exp Pathol (2011) 0.78
Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother (2002) 0.77
Infections of cardiac implantable electronic devices: a retrospective multicenter observational study. Medicine (Baltimore) (2012) 0.77
Systemic antifungal therapy in patients without documented invasive fungal infection: a peek into the world of empirical antifungal therapy*. Crit Care Med (2012) 0.76
Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. Mycoses (2009) 0.76
Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). Am J Med (2011) 0.76
Reply to "Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!". J Clin Microbiol (2013) 0.75
Prophylaxis for invasive candidiasis in the intensive care unit: is it time? Crit Care Med (2005) 0.75
Medical order formatting in the era of patient safety. Crit Care Med (2004) 0.75
Invasive candidiasis in the intensive care unit. Hosp Pract (1995) (2010) 0.75
The CTSA University of Texas Health Science Center (UTHSC) Northeast-Tyler and Rio Grande Valley Success Story: How Rural, Underserved Academic Communities Rapidly Built a Robust Engine for Collaborative COVID-19 Clinical Research. J Health Care Poor Underserved (2022) 0.75
Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions. Expert Opin Pharmacother (2005) 0.75
Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation. Pharmacotherapy (2005) 0.75
Prevalence and risk factors of methicillin-resistant Staphylococcus aureus colonization among critically ill hospitalized patients in a tertiary care center in Houston, Texas: an active surveillance pilot project. Infect Control Hosp Epidemiol (2010) 0.75